Iranian Journal of Pathology

Evaluation of Secondary Bacterial Infections and Determination of Antibiogram Susceptibility Testing in Hospitalized Patients with COVID-19

Document Type : Original Research

Authors

Tahmineh Mollasharifi 1
Mahmoud Zamani 2
Atoosa Gharib 2

1 Department of Pathology, Clinical Research Development Center, Shahid Modarres Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 Department of Pathology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

https://doi.org/10.30699/ijp.2024.2006587.3141
Abstract
Background & Objective: COVID-19 is a global pandemic that has caused an increase in hospitalization rates and high mortality. Secondary bacterial infections in hospitalized patients are one of the common complications of this viral disease. Due to the increased prevalence of antibiotic resistance, treating these patients is challenging. Therefore, this study aimed to evaluate the secondary bacterial infection and antimicrobial sensitivity test in hospitalized patients with COVID-19 in a tertiary hospital.
Methods: In this retrospective descriptive study, all patients with COVID-19 who were admitted to Shahid Modares Hospital (Tehran-Iran) from October 2020 to March 2021 with positive culture results for bacterial infections, were assessed. The significance level was lower than 0.05.
Results: Ninety-seven patients with a mean age of 65.23 ± 16.72 years were assessed. The male patients accounted for 58.8% of the patients, while 41.2% were female. The ICU admitted patients with critical COVID-19 severity accounted for 59.8%, while 40.2% were hospitalized in the ward with a severe form of the disease. Age, length of hospitalization, and mortality rate were significantly higher in patients with ICU admission (all P-values<0.05). The most antibiotic-resistant bacteria were Klebsiella pneumoniae (32.98%). ICU admission showed a significantly higher rate in patients who were resistant to Cefotaxime, Ceftriaxone, Gentamicin, and Co-trimoxazole compared to the patients who were hospitalized in the ward (all P-values<0.05).
Conclusion: Secondary bacterial infection in hospitalized patients with COVID-19 may lead to high mortality.

Keywords

COVID-19
Coinfection
Drug resistance
Intensive care unit

Subjects

  1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533-4. [DOI:10.1016/S1473-3099(20)30120-1] [PMID]
  2. Ripa M, Galli L, Poli A, Oltolini C, Spagnuolo V, Mastrangelo A, et al. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. Clin Microbiol Infect. 2021;27(3):451-7. [DOI:10.1016/j.cmi.2020.10.021] [PMID]
  3. Sharifipour E, Shams S, Esmkhani M, Khodadadi J, Fotouhi-Ardakani R, Koohpaei A, et al. Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU. BMC Infect Dis. 2020;20(1):1-7. [DOI:10.1186/s12879-020-05374-z] [PMID]
  4. Klein EY, Monteforte B, Gupta A, Jiang W, May L, Hsieh YH, et al. The frequency of influenza and bacterial coinfection: a systematic review and meta‐analysis. Influ Other Respir Viruses. 2016;10(5):394-403. [DOI:10.1111/irv.12398] [PMID]
  5. Alhazzani W, Evans L, Alshamsi F, Møller MH, Ostermann M, Prescott HC, et al. Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update. Crit Care Med. 2021;49(3):e219-e34. [PMID] [DOI:10.1097/CCM.0000000000004899]
  6. Organization WH. Evidence to recommendations: methods used for assessing health equity and human rights considerations in COVID-19 and aviation: interim guidance, 23 December 2020. World Health Organization; 2020.
  7. Cox MJ, Loman N, Bogaert D, O'Grady J. Co-infections: potentially lethal and unexplored in COVID-19. The Lancet Microbe. 2020;1(1):e11. [DOI:10.1016/S2666-5247(20)30009-4] [PMID]
  8. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26(12):1622-9. [DOI:10.1016/j.cmi.2020.07.016] [PMID] 
  9. Goetz M, Graber C, Jones M. Antibiotic use at veterans affairs' hospitals increases during COVID-19 pandemic, reversing a four-year downward trend, 2020.
  10. Baghdadi JD, Coffey K, Adediran T, Goodman KE, Pineles L, Magder LS, et al. Antibiotic use and bacterial infection among inpatients in the first wave of COVID-19: a retrospective cohort study of 64,691 patients. Antimicrob Agents Chemother. 2021;65(11): e01341-21. [DOI:10.1128/AAC.01341-21] [PMID]
  11. Goncalves Mendes Neto A, Lo KB, Wattoo A, Salacup G, Pelayo J, DeJoy III R, et al. Bacterial infections and patterns of antibiotic use in patients with COVID‐19. J Med Virol. 2021;93(3):1489-95. [DOI:10.1002/jmv.26441] [PMID]
  12. Rawson TM, Moore LS, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020;71(9):2459-68. [DOI:10.1093/cid/ciaa530] [PMID]
  13. Russell CD, Fairfield CJ, Drake TM, Turtle L, Seaton RA, Wootton DG, et al. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe. 2021;2(8):e354-e65. [DOI:10.2139/ssrn.3786694]
  14. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with different severities: a multicenter study of clinical features. Am J Respir Crit Care Med. 2020;201(11):1380-8. [DOI:10.1164/rccm.202002-0445OC] [PMID] 
  15. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. [DOI:10.1016/S0140-6736(20)30566-3] [PMID]
  16. Budinger GS, Misharin AV, Ridge KM, Singer BD, Wunderink RG. Distinctive features of severe SARS-CoV-2 pneumonia. The Journal of clinical investigation. 2021;131(14). [DOI:10.1172/JCI149412] [PMID]
  17. Lai C-C, Chen S-Y, Ko W-C, Hsueh P-R. Increased antimicrobial resistance during the COVID-19 pandemic. International journal of antimicrobial agents. 2021;57(4):106324. [DOI:10.1016/j.ijantimicag.2021.106324] [PMID]
  18. Hsu J. How covid-19 is accelerating the threat of antimicrobial resistance. Bmj. 2020;369. [DOI:10.1136/bmj.m1983] [PMID]
  19. Monnet DL, Harbarth S. Will coronavirus disease (COVID-19) have an impact on antimicrobial resistance? : European Centre for Disease Prevention and Control (ECDC); 2020. p. 2001886. [DOI:10.2807/1560-7917.ES.2020.25.45.2001886]
  20. Pourajam S, Kalantari E, Talebzadeh H, Mellali H, Sami R, Soltaninejad F, et al. Secondary bacterial infection and clinical characteristics in patients with COVID-19 admitted to two intensive care units of an academic hospital in Iran during the first wave of the pandemic. Frontiers in cellular and infection microbiology. 2022:141. [DOI:10.3389/fcimb.2022.784130] [PMID]
  21. Weinstein MP, Lewis JS. The clinical and laboratory standards institute subcommittee on antimicrobial susceptibility testing: background, organization, functions, and processes. Journal of clinical microbiology. 2020;58(3):e01864-19. [DOI:10.1128/JCM.01864-19] [PMID] 
  22. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. jama. 2020;323(13):1239-42. [DOI:10.1001/jama.2020.2648] [PMID]
  23. Costa RLd, Lamas CdC, Simvoulidis LFN, Espanha CA, Moreira LPM, Bonancim RAB, et al. Secondary infections in a cohort of patients with COVID-19 admitted to an intensive care unit: impact of gram-negative bacterial resistance. Revista do Instituto de Medicina Tropical de São Paulo. 2022;64. [DOI:10.1590/s1678-9946202264006] [PMID]
  24. Li J, Wang J, Yang Y, Cai P, Cao J, Cai X, et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis. Antimicrobial Resistance & Infection Control. 2020;9(1):1-7. [DOI:10.1186/s13756-020-00819-1] [PMID] 
  25. Contou D, Claudinon A, Pajot O, Micaëlo M, Longuet Flandre P, Dubert M, et al. Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. Annals of intensive care. 2020;10:1-9. [DOI:10.1186/s13613-020-00736-x] [PMID]
  26. Bahceci I, Yildiz IE, Duran OF, Soztanaci US, Harbawi ZK, Senol FF, et al. Secondary bacterial infection rates among patients with COVID-19. Cureus. 2022;14(2). [DOI:10.7759/cureus.22363] [PMID]
  27. Baskaran V, Lawrence H, Lansbury LE, Webb K, Safavi S, Zainuddin NI, et al. Co-infection in critically ill patients with COVID-19: an observational cohort study from England. J Med Microbiol. 2021;70(4). [DOI:10.1099/jmm.0.001350] [PMID]
  28. Karataş M, Yaşar-Duman M, Tünger A, Çilli F, Aydemir Ş, Özenci V. Secondary bacterial infections and antimicrobial resistance in COVID-19: comparative evaluation of pre-pandemic and pandemic-era, a retrospective single center study. Ann Clin Microbiol Antimicrob. 2021;20:1-8. [DOI:10.1186/s12941-021-00454-7] [PMID]
Iranian Journal of Pathology
Volume 19, Issue 4
Autumn 2024
Pages 392-399

  • Receive Date 09 February 2024
  • Revise Date 27 January 2024
  • Accept Date 18 July 2024

Home

Guide for Authors

Submit Manuscript

Contact Us